Reports
Reports
Sale
Eli Lilly and Company is a pharmaceutical company based in the United States, with their headquarters in Indiana. They distribute their products in approximately 125 countries. The company has been in service since 1876. The company works on multiple diseases including Alzheimer’s, Cancer, Diabetes, Immunology, Obesity, and Pain.
AbbVie Inc. is an American pharmaceutical research and development company, which was founded in 2013. They provide therapeutic services for various areas of disease such as neuroscience, virology, oncology, immunology, and eye care. The company is increasingly invested to develop and deliver new medications.
Alkermes PLC is one of the key global biopharmaceutical companies, which was founded in 1987 and is headquartered in Ireland. The company is engaged in the development of innovative medicines in the medical field of neuroscience and oncology.
Other Key players include Otsuka Pharmaceutical Co., Ltd., and Johnson & Johnson Services, Inc., among others.
Schizophrenia Drugs Market Size
Schizophrenia Drugs Market Analysis
Schizophrenia Drugs Treatment Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Schizophrenia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Schizophrenia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Schizophrenia Epidemiology (2016-2031)
5.3 Europe Schizophrenia Epidemiology (2016-2031)
5.4 Asia-Pacific Schizophrenia Epidemiology (2016-2031)
5.5 Latin America Schizophrenia Epidemiology (2016-2031)
5.6 Middle East & Africa Schizophrenia Epidemiology (2016-2031)
6 Global Schizophrenia Drugs Market Overview
6.1 Global Schizophrenia Drugs Market Historical Value (2017-2023)
6.2 Global Schizophrenia Drugs Market Forecast Value (2024-2032)
7 Global Schizophrenia Drugs Market Landscape
7.1 Schizophrenia Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Schizophrenia Drugs: Product Landscape
7.2.1 Analysis by Therapeutic Class
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Distribution Channels
8 Schizophrenia Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Schizophrenia Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Schizophrenia Drugs Market Segmentation
11.1 Global Schizophrenia Drugs Market by Therapeutic Class
11.1.1 Market Overview
11.1.2 Second-generation Antipsychotics
11.1.3 Third-generation Antipsychotics
11.1.4 Others
11.2 Global Schizophrenia Drugs Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Injectables
11.3 Global Schizophrenia Drugs Market by Distribution Channels
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online
11.3.5 Others
11.4 Global Schizophrenia Drugs Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Schizophrenia Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Schizophrenia Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Schizophrenia Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Schizophrenia Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Schizophrenia Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Eli Lilly and Company
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 AbbVie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Alkermes PLC
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Otsuka Pharmaceutical Co., Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Johnson & Johnson Services, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Pfizer Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 AstraZeneca
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Bristol Myers Squibb
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Sumitomo Dainippon Pharma Co., Ltd.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Vanda Pharmaceuticals Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Schizophrenia Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market is expected to grow at a CAGR of 3.9% during the period 2024-2032.
The market is driven by the increasing number of cases of schizophrenia and the wide adoption of long-acting injectables due to their benefits of reduced relapse of the patient.
The rising investment and industrial collaborations in the development of novel treatments for schizophrenia are key trends followed in the market.
The regional markets for the global schizophrenia drugs market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The different therapeutic classes in the market include second-generation antipsychotics and third-generation antipsychotics, among others.
The different types of treatment in the market include oral and injectables.
The distribution channels used for schizophrenia drugs include hospital pharmacies, retail pharmacies, and online, among others.
The key players in the market include Eli Lilly and Company, AbbVie Inc., Alkermes PLC, Otsuka Pharmaceutical Co., Ltd., and Johnson & Johnson Services, Inc., among others.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.